lead-time bias

**Definition:** Lead-time bias is a systematic error in which a screening test detects disease earlier in its natural history, so measured survival from diagnosis is longer even if screening does not delay death. Lead time = time between detection by screening and the usual clinical diagnosis (when symptoms would have prompted it).

**Example:** A cancer is detected by screening at age 60 and the patient dies at age 70, so survival is 10 years. Without screening, the cancer would have been diagnosed at age 67 from symptoms, and the patient would still have died at age 70, so survival would be 3 years. Screening made survival look 7 years longer, but the patient did not live any longer. The only change is that they knew about the disease for more time.

**Pathophysiology/Concept:** Survival is measured from the date of diagnosis. Screening moves that date earlier. The "clock" starts sooner, but the biologic course and the time of death stay the same unless early treatment actually changes the disease course.

**Clinical significance:** - It is a major reason that 5-year survival is a misleading metric for judging screening programs (for example, the 5-year survival rate for screen-detected cancers looks better). - It affects the evaluation of any screening test (mammography, PSA, low-dose CT for lung cancer, colonoscopy). - True benefit has to be shown with a reduction in disease-specific or all-cause mortality, not with improved survival time after diagnosis.

**How to correct for or avoid it:** - Use mortality rates (disease-specific mortality in the whole screened vs. unscreened population) as the endpoint instead of survival from diagnosis. - Use randomized controlled trials of screened vs. unscreened groups that compare mortality. - Adjust survival by subtracting the estimated lead time from the screened group's survival.

**Related biases (commonly tested together):** - **Length-time bias:** Screening preferentially detects slower-growing, less aggressive (indolent) disease with a longer preclinical phase, while fast-growing aggressive disease often presents between screenings. This makes screen-detected cases seem to have a better prognosis. - **Selection bias (volunteer/healthy-screenee effect):** People who choose screening tend to be healthier and have better outcomes. - **Overdiagnosis:** Detecting disease that would never have caused symptoms or death (for example, indolent prostate cancer).

**Board pearls:** - The classic stem is a new screening test, with "survival" going up from 3 to 10 years but the mortality rate unchanged. The answer is lead-time bias. - Lead-time bias applies to the time of diagnosis, so the apparent survival gain does not reflect delayed death. - It is a type of measurement bias. - Length-time bias is about the type of disease detected (slow vs. fast). Lead-time bias is about the timing of detection.